These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Fauconneau A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, Dalle S, Joly P, Viraben R, Franck F, Ingen-Housz-Oro S, Giacchero D, Jullié ML, Vergier B, Merlio JP, Beylot-Barry M. Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336 [Abstract] [Full Text] [Related]
3. Prognostic Significance of CD30 in Transformed Mycosis Fungoides. Travaglino A, Russo D, Varricchio S, Pignatiello S, Baldo A, Picardi M, Pane F, Mascolo M. Am J Clin Pathol; 2021 Aug 04; 156(3):350-355. PubMed ID: 33769436 [Abstract] [Full Text] [Related]
8. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma. Gao C, McCormack CJ, van der Weyden C, Twigger R, Buelens O, Lade S, Khoo C, Campbell BA, Goh M, McKelvie P, Prince HM. J Am Acad Dermatol; 2021 Jan 04; 84(1):185-187. PubMed ID: 32334059 [No Abstract] [Full Text] [Related]
9. Primary cutaneous anaplastic large cell lymphoma. Brown RA, Fernandez-Pol S, Kim J. J Cutan Pathol; 2017 Jun 04; 44(6):570-577. PubMed ID: 28342276 [Abstract] [Full Text] [Related]
10. CD30+ leukemic cutaneous T-cell lymphoma. Ellis A, Christensen LF, Sharma T, Meyerson H, Kord H, Cooper KD. J Am Acad Dermatol; 2021 Feb 04; 84(2):530-532. PubMed ID: 32437721 [No Abstract] [Full Text] [Related]
11. A case of mycosis fungoides after CD30 positive anaplastic large cell lymphoma. Lee MW, Chi DH, Choi JH, Sung KJ, Moon KC, Koh JK. J Dermatol; 2000 Jul 04; 27(7):458-61. PubMed ID: 10935344 [Abstract] [Full Text] [Related]
12. Response of CD30+ large cell lymphoma of skin to bexarotene. Keun YK, Woodruff R, Sangueza O. Leuk Lymphoma; 2002 May 04; 43(5):1153-4. PubMed ID: 12148901 [Abstract] [Full Text] [Related]
13. Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data. Enos TH, Feigenbaum LS, Wickless HW. Int J Dermatol; 2017 Dec 04; 56(12):1400-1405. PubMed ID: 28762479 [Abstract] [Full Text] [Related]
14. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Nguyen GH, Olson LC, Magro CM. Ann Diagn Pathol; 2017 Jun 04; 28():54-59. PubMed ID: 28648940 [Abstract] [Full Text] [Related]
15. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome. Danish HH, Liu S, Jhaveri J, Flowers CR, Lechowicz MJ, Esiashvili N, Khan MK. Leuk Lymphoma; 2016 Dec 04; 57(12):2813-2819. PubMed ID: 27104864 [Abstract] [Full Text] [Related]
16. CD4/CD8 double-negative early-stage mycosis fungoides with CD30 expression. Shon U, Yun DK, Seong GH, Park BC, Kim MH, Lee DY. J Cutan Pathol; 2021 Apr 04; 48(4):587-589. PubMed ID: 32789870 [No Abstract] [Full Text] [Related]
18. Mycosis fungoides with CD30-positive cells in the epidermis. Wu H, Telang GH, Lessin SR, Vonderheid EC. Am J Dermatopathol; 2000 Jun 04; 22(3):212-6. PubMed ID: 10871063 [Abstract] [Full Text] [Related]
19. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. Raghavan SS, Hong EK, Kim YH, Kim J. J Cutan Pathol; 2019 Jan 04; 46(1):33-43. PubMed ID: 30328119 [Abstract] [Full Text] [Related]
20. Mycosis fungoides with CD30-positive large-cell transformation clinically mimicking scarring alopecia. Bidier M, Pushkarevskaya A, Enk A, Hartmann M, Toberer F. J Dtsch Dermatol Ges; 2017 Oct 04; 15(10):1021-1023. PubMed ID: 28834192 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]